Last reviewed · How we verify
NCT04774471
Advanced Diffusion Tensor MRI for Breast Cancer
trial testing Evaluation of BIT-Motion software in Breast Cancer in 68 participants. Completed in 18 May 2023.
18 May 2023
Quick facts
| Lead sponsor | Endeavor Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 68 |
| Start date | 3 February 2021 |
| Primary completion | 18 May 2023 |
| Estimated completion | 18 May 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Evaluation of BIT-Motion software
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Diseases — all drugs for Breast Diseases →
Sponsor
Endeavor Health — full company profile →
Who can join
18 and older, female only, with Breast Cancer or Breast Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research is to evaluate the accuracy of the BIT-Motion (Breast Imaging Tensor-Motion) software with non-contrast MRI scanning to detect breast cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04774471
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Endeavor Health trials
Trials by the same sponsor.
- NCT06258785 — Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension · Phase 3 · completed
- NCT06279195 — Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment · Phase 2 · withdrawn
- NCT05921149 — Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer · NA · not yet recruiting
- NCT05747027 — Prospective Randomized Controlled Trial of Obstructed Defecation Surgery · NA · terminated
- NCT06062875 — Effects of TNF Blockade on Human BPH/LUTS · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04774471 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Endeavor Health
- Last refreshed: 3 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04774471.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing